• Publications
  • Influence
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
TLDR
Ketamine demonstrated rapid antidepressant effects in an optimized study design, further supporting NMDA receptor modulation as a novel mechanism for accelerated improvement in severe and chronic forms of depression. Expand
Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression
TLDR
Ketamine was associated with a rapid antidepressant effect in TRD that was predictive of a sustained effect and future controlled studies will be required to identify strategies to maintain an antidepressant response among patients who benefit from a course of ketamine. Expand
Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression
TLDR
These pilot findings suggest feasibility of repeated-dose IV ketamine for the acute treatment of TRD and change from baseline in the Montgomery-Asberg Depression Rating Scale score. Expand
Effects of Intravenous Ketamine on Explicit and Implicit Measures of Suicidality in Treatment-Resistant Depression
TLDR
Preliminary findings support the premise that ketamine has rapid beneficial effects on suicidal cognition and warrants further study. Expand
Ketamine for Depression: Where Do We Go from Here?
TLDR
Risk-benefit analyses support further research of ketamine for individuals with severe mood disorders, but given the paucity of randomized controlled trials, lack of an active placebo, limited data on long-term outcomes, and potential risks, ketamine administration is not recommended outside of the hospital setting. Expand
Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial.
TLDR
This pilot study showed that a sub-anaesthetic dose of i.v. ketamine is well-tolerated in TRD, and may have rapid and sustained antidepressant properties, and riluzole did not prevent relapse in the first month following ketamine. Expand
Neurobiological mechanisms in major depressive disorder
TLDR
Data is discussed describing how genes, psychosocial adversity in childhood, and ongoing or recentPsychosocial stress may impact multiple neurobiological systems relevant to major depressive episodes. Expand
EFFECTS OF KETAMINE ON EXPLICIT AND IMPLICIT SUICIDAL COGNITION: A RANDOMIZED CONTROLLED TRIAL IN TREATMENT‐RESISTANT DEPRESSION
TLDR
In the first randomized controlled trial of ketamine using an anesthetic control condition, ketamine's acute effects on explicit suicidal cognition and a performance‐based index of implicit suicidal cognition (IAT) previously linked to suicidal behavior are tested. Expand
Twenty-four-hour cortisol secretion patterns in prepubertal children with anxiety or depressive disorders
TLDR
Anxious children seem to exhibit an altered pattern of nighttime cortisol secretion, with an initially sluggish or delayed nocturnal rise before reaching similar peak levels of cortisol near the time of awakening, which suggest subtle alterations in HPA axis function in prepubertal children with anxiety disorders. Expand
Dorsolateral prefrontal cortical pathology in generalized anxiety disorder: a proton magnetic resonance spectroscopic imaging study.
TLDR
Generalized anxiety disorder is associated with asymmetric increases in the N-acetylaspartate/creatine ratio, a suggested marker of neuronal viability, in the prefrontal cortex, which supports prior research linking childhood abuse to reduced neuronal viability. Expand
...
1
2
3
4
5
...